Citations

Clear

4799 citation(s) found for "Yu, Jennifer".

IC‐04‐02: ANTEMORTEM VOLUME LOSS MIRRORS TDP43 STAGING IN NON‐FTLD OLDER ADULTS
Martin, Peter R. , Tosakulwong, Nirubol , Petersen, Ronald C. , Parisi, Joseph E., Whitwell, Jennifer L. , Josephs, Keith A. , Bejanin, Alexandre , Murray, Melissa E. , Botha, Hugo , Schwarz, Christopher G. , Senjem, Matthew L. , Chételat, Gaël , Jack, Clifford R. , Boeve, Bradley F. , Knopman, David S. , Giannini, Caterina , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2019.06.4152 Get It

P4‐330: LONGITUDINAL BEHAVIOR OF BETA‐AMYLOID IN NEURODEGENERATIVE DEMENTIAS
Whitwell, Jennifer L. , Tosakulwong, Nirubol , Weigand, Stephen D. , Graff‐Radford, Jonathan , Ertekin‐Taner, Nilüfer , Lowe, Val J. , Josephs, Keith A. , Duffy, Joseph R. , Clark, Heather M. , Machulda, Mary M. , Botha, Hugo , Utianski, Rene L. , Schwarz, Christopher G. , Senjem, Matthew L. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_27 | Pages: No page available

10.1016/j.jalz.2019.06.4000 Get It

P1‐311: DEVELOPMENT OF AN INTERNATIONAL POSTERIOR CORTICAL ATROPHY BIOREGISTRY
Pelak, Victoria S. , Tang‐Wai, David F. , Onyike, Chiadi U. , Olds, Jennifer, Hills, William L., Bretsch, Candace, Lusk, Jerri, Boyd, Timothy, Pressman, Peter , Holden, Samantha K. , Bettcher, Bri M., Bouwman, Femke H. , Murray, Melissa E. , Day, Gregory S. , Migliaccio, Raffaella Lara , Potter, Huntington , Boyd, Timothy D.

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_7 | Pages: No page available

10.1016/j.jalz.2019.06.866 Get It

Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping
Shlensky, Julia A , Thurber, Kristina M., O’Meara, John G. , Ou, Narith N., Osborn, Jennifer L., Dierkhising, Ross , Mara, Kristin C. , Bierle, Dennis M. , Daniels, Paul R. , Dierkhising, Ross A, Mara, Kristin C , Osborn, Jennifer L

Mayo Clinic

Vascular Medicine | October 18, 2019 | Volume: 25 | Issue: 1 | Pages: 47-54

10.1177/1358863x19875813 | PMID 31623539 Get It

Controversy exists regarding the use of dose capping of weight-based unfractionated heparin (UFH) infusions in obese and morbidly obese patients. The primary objective of this study was to compare time to first therapeutic activated partial thromboplastin time (aPTT) in hospitalized patients receiving UFH for acute venous thromboembolism (VTE) among three body mass index (BMI) cohorts: non-obese (< 30 kg/m 2 ), obese (30–39.9 kg/m 2 ), and morbidly obese (⩾ 40 kg/m 2 ). In this single-center, retrospective cohort study, patients were included if they ⩾ 18 years of age, had a documented VTE, and were on an infusion of UFH for at least 24 hours. Weight-based UFH doses were calculated using actual body weight. A total of 423 patients met the inclusion criteria, with 230 (54.4%), 146 (34.5%), and 47 (11.1%) patients in the non-obese, obese, and morbidly obese cohorts, respectively. Median times to therapeutic aPTT were 16.4, 16.6, and 17.1 hours in each cohort. Within 24 hours, the cumulative incidence rates for therapeutic aPTT were 70.7% for the non-obese group, 69.9% for the obese group, and 61.7% for the morbidly obese group (obese vs non-obese: HR = 1.02, 95% CI: 0.82–1.26, p = 0.88; morbidly obese vs non-obese: HR = 0.87, 95% CI: 0.62–1.21, p = 0.41). There was no significant difference in major bleeding events between BMI groups (obese vs non-obese, p = 0.91; morbidly obese vs non-obese, p = 0.98). Based on our study, heparin dosing based on actual body weight without a dose cap is safe and effective.
Vaping-Associated Lung Injury
Boland, Jennifer M. , Aesif, Scott W.

Mayo Clinic

American Journal of Clinical Pathology | October 17, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajcp/aqz191 | PMID 31651033 Get It

Exercise is medicine in oncology: Engaging clinicians to help patients move through cancer
Schmitz, Kathryn H. , Campbell, Anna , Stuiver, Martijn M. , Pinto, Bernardine M. , Schwartz, Anna L. , Morris, Gerwyn , Ligibel, Jennifer A. , Galvão, Daniel A. , Alfano, Catherine M. , Patel, Alpa V. , Hue, Trisha F. , Sallis, Robert E. , Stout, Nicole L. , Chan, Leighton , Flowers, Fiona, Doyle, Colleen, Helmrich, Susan P., Sokolof, Jonas, Campbell, Kristin L. , Campbell, Anna M , Galvão, Daniel A , Alfano, Catherine M , Gerber, Lynn H , Gusani, Niraj J , Winters-Stone, Kerri M , Campbell, Kristin L , Matthews, Charles E , Schmitz, Kathryn H , Morris, G. Stephen, Cheville, Andrea , Gerber, Lynn H. , Gusani, Niraj J. , Bain, William, Winters‐Stone, Kerri M.

Mayo Clinic

CA: A Cancer Journal for Clinicians | October 16, 2019 | Volume: 69 | Issue: 6 | Pages: 468-484

10.3322/caac.21579 | PMID 31617590 Get It

Multiple organizations around the world have issued evidence‐based exercise guidance for patients with cancer and cancer survivors. Recently, the American College of Sports Medicine has updated its exercise guidance for cancer prevention as well as for the prevention and treatment of a variety of cancer health‐related outcomes (eg, fatigue, anxiety, depression, function, and quality of life). Despite these guidelines, the majority of people living with and beyond cancer are not regularly physically active. Among the reasons for this is a lack of clarity on the part of those who work in oncology clinical settings of their role in assessing, advising, and referring patients to exercise. The authors propose using the American College of Sports Medicine's Exercise Is Medicine initiative to address this practice gap. The simple proposal is for clinicians to assess, advise, and refer patients to either home‐based or community‐based exercise or for further evaluation and intervention in outpatient rehabilitation. To do this will require care coordination with appropriate professionals as well as change in the behaviors of clinicians, patients, and those who deliver the rehabilitation and exercise programming. Behavior change is one of many challenges to enacting the proposed practice changes. Other implementation challenges include capacity for triage and referral, the need for a program registry, costs and compensation, and workforce development. In conclusion, there is a call to action for key stakeholders to create the infrastructure and cultural adaptations needed so that all people living with and beyond cancer can be as active as is possible for them.
Evaluation of a novel technique involving ultrasound-guided, temporary, percutaneous gastropexy and gastrostomy catheter placement for providing sustained gastric decompression in dogs with gastric dilatation-volvulus
Fox‐Alvarez, W. Alexander, Case, Jennifer, Joyce, Ashley C., Cooke, Kirsten L. , Toskich, Beau B. , Case, J. Brad, Lewis, Daniel Dean

Mayo Clinic

Journal of the American Veterinary Medical Association | October 16, 2019 | Volume: 255 | Issue: 9 | Pages: 1027-1034

10.2460/javma.255.9.1027 | PMID 31617809 Get It

Abstract OBJECTIVE To evaluate the feasibility of ultrasound-guided, temporary, percutaneous T-fastener gastropexy (TG) and gastrostomy catheter (GC) placement for providing sustained gastric decompression in dogs with acute gastric dilatation-volvulus (GDV) and to compare findings with those of trocarization. ANIMALS 16 dogs with GDV. PROCEDURES Dogs were randomly assigned to undergo gastric decompression by means of percutaneous trocarization (trocar group; n = 8) or temporary TG and GC placement (TTG+GC group; 8) with ultrasound guidance. The gastric volvulus was then surgically corrected, and the decompression sites were examined. Outcomes were compared between groups. RESULTS The proportion of dogs with successful decompression did not differ significantly between the TTG+GC (6/8) and trocar (7/8) groups; median procedure duration was 3.3 and 3.7 minutes, respectively. After the failed attempts in the TTG+GC group, the procedure was modified to include ultrasound guidance during T-fastener placement. The decrease in intragastric pressure by 5 minutes after trocar or GC insertion was similar between groups. For dogs in the TTG+GC group, no significant difference in intragastric pressure was identified between 5 and 60 minutes after GC insertion. Complications included inadvertent splenic or jejunal placement in 2 dogs (TTG+GC group) and malpositioned and ineffective trocar placement in 1 dog (trocar group). All dogs survived for at least 2 weeks. CONCLUSIONS AND CLINICAL RELEVANCE Ultrasound-guided, temporary, percutaneous TG and GC placement was safe and effective at providing sustained gastric decompression in dogs with GDV, suggesting that this technique would be ideal for dogs in which surgical delays are anticipated or unavoidable.
Estrogen receptors differentially regulate intracellular calcium handling in human nonasthmatic and asthmatic airway smooth muscle cells
Bhallamudi, Sangeeta, Connell, Jennifer , Prakash, Y. S. , Sathish, Venkatachalem , Prakash, Y S , Sathish, Venkatachalem , Pabelick, Christina M.

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | October 16, 2019 | Volume: 318 | Issue: 1 | Pages: L112-L124

10.1152/ajplung.00206.2019 | PMID 31617730 Get It

Asthma is defined as chronic inflammation of the airways and is characterized by airway remodeling, hyperresponsiveness, and acute bronchoconstriction of airway smooth muscle (ASM) cells. Clinical findings suggest a higher incidence and severity of asthma in adult women, indicating a concrete role of sex steroids in modulating the airway tone. Estrogen, a major female sex steroid mediates its role through estrogen receptors (ER) ERα and ERβ, which are shown to be expressed in human ASM, and their expression is upregulated in lung inflammation and asthma. Previous studies suggested rapid, nongenomic signaling of estrogen via ERs reduces intracellular calcium ([Ca2+]i), thereby promoting relaxation of ASM. However, long-term ER activation on [Ca2+]iregulation in human ASM during inflammation or in asthma is still not known. In Fura-2-loaded nonasthmatic and asthmatic human ASM cells, we found that prolonged (24 h) exposure to ERα agonist (PPT) increased [Ca2+]iresponse to histamine, whereas ERβ activation (WAY) led to decreased [Ca2+] compared with vehicle. This was further confirmed by ER overexpression and knockdown studies using various bronchoconstrictor agents. Interestingly, ERβ activation was more effective than 17β-estradiol in reducing [Ca2+]iresponses in the presence of TNF-α or IL-13, while no observable changes were noticed with PPT in the presence of either cytokine. The [Ca2+]i-reducing effects of ERβ were mediated partially via L-type calcium channel inhibition and increased Ca2+sequestration by sarcoplasmic reticulum.Overall, these data highlight the differential signaling of ERα and ERβ in ASM during inflammation. Specific ERβ activation reduces [Ca2+]iin the inflamed ASM cells and is likely to play a crucial role in regulating ASM contractility, thereby relaxing airways.
Frequency of Acquired Genetic Mutations and Their Prognostic Impact on Patients with Incidental Finding of Isolated 20q- in Bone Marrow without Morphologic Evidence of a Myeloid Neoplasm
He, Rong , Jawad, Majd, Oliveira, Jennifer L. , Nguyen, Phuong L., Viswanatha, David S., Reichard, Kaaren K. , Hoyer, James D., Ravindran, Aishwarya , Ketterling, Rhett P. , Chen, Dong , Go, Ronald S. , Shi, Min

Mayo Clinic

Blood | October 14, 2019 | Volume: 132 | Issue: Supplement 1 | Pages: 4382-4382

10.1182/blood-2018-99-117821 Get It

Abstract Introduction Myelodysplastic syndromes (MDS) are heterogeneous myeloid disorders characterized by dysplasia in one or more hematopoietic cell lines, peripheral cytopenia(s), and distinct cytogenetic abnormalities. The presence of certain cytogenetic abnormalities [e.g. 7/del(7q), -5/del(5q), 13/del(13q), i(17p)], in the setting of unexplained persistent cytopenia, has been considered presumptive evidence of MDS, despite definitive morphologic features of MDS. Conversely, chromosomal abnormalities such as isolated 20q- are not considered definitive evidence for MDS, in the absence of dysplasia. Based on our previous findings, patients with isolated 20q- without morphologic features of a myeloid neoplasm have varied clinical outcomes (Jawad MD et al. Am J Hematol.2016). In this study, we investigate the frequency of recurrent somatic gene mutations in these patients, and their relationship to progression to a myeloid neoplasm. Methods We retrospectively reviewed the bone marrow pathology reports of patients evaluated at our institution from 01/2005 to 09/2015 who had isolated 20q- in at least 2 of 20 metaphases. Patients with isolated 20q- and without myeloid neoplasms were included in the study, along with medical record review. A 35-gene next generation sequencing (NGS) panel (OncoHeme) targeting myeloid neoplasms was performed on available archived bone marrow aspirate pellets. Statistical analyses were performed using JMP Pro software version 13. Parametric (t-test) or nonparametric tests such as the Fisher-exact test, chi-square test, or Wilcoxon rank-sum test, were utilized as appropriate for test variables. Statistical significance was based on a 2-sided significance level of .05. Kaplan-Meier analysis was used for analyzing time to progression to myeloid neoplasms and progression-free survival (i.e. time to progression to myeloid neoplasms or death from any cause). Results Fifty-six (42 males, 14 females) patients with isolated 20q- were identified. The average percentage of 20q- was 38.5 % (±29.3). The median age was 68 years (range: 44-90) and the median hemoglobin (Hb), absolute neutrophil count (ANC) and platelet count (Plt) were 11.7 g/dL (range: 8.3-15.1), 2.7 x 10(9)/L (range: 0.6-9.4) and 138 x 10(9)/L (range: 16-392), respectively. The indications for bone marrow biopsies ranged from cytopenia (21), multiple myeloma (20), non-Hodgkin lymphoma (10), amyloidosis (2), CLL (2) and transplant donor evaluation (1). Twenty-three patients harbored pathogenic mutations (15 had one mutation, 1 had two mutations and 7 had three mutations). The identified pathogenic mutations included ASXL1 (8), TET2 (8), SRSF2(3),PHF6 (2), SF3B1 (2), CBL (2), U2AF1 (2), IDH1 (1), IDH2 (1), BCOR (1), JAK2 (1), PTPN11(1), TP53 (1) and RUNX1 (1). Nine patients (16.1%) progressed to myeloid neoplasms (5 MDS, 2 acute myeloid leukemia, 2 chronic myeloid neoplasm-not otherwise specified) at a median follow-up of 36.7 months (range: 1.9-57.4). Of these 9 patients, 5 had one mutation (BCOR, TET2, DNM3TA, CBL, IDH2), 1 had two mutations (SF3B1/CBL) and 3 had three mutations (ASXL1/IDH1/SRSF2,DNM3TA/PTPN11/TET2, PHF6/TET2/TET2). In contrast, only 29.8% of non-progressed cases showed at least 1 mutation. Kaplan-Meier analysis demonstrated the presence of genetic mutations in patients with isolated 20q- carried significantly higher chance of progression to myeloid neoplasms (p<.05, Figure 1A and 1B). However, the number of genetic mutations was not predictive of progression in our relatively small study cohort (p=.66). There was no significant difference between those who did and did not progress with respect to age, gender, Hb, ANC, Plt, 20q- or mutational allele burden. Conclusions Most of the patients with isolated 20q- and without morphologic features of a myeloid neoplasm did not harbor myeloid neoplasm associated gene mutations and further did not develop a myeloid neoplasm during the course of our study. Among patients with pathogenic mutations, nearly one-third showed progression to a myeloid neoplasm. Of the clinical and laboratory variables, the presence of genetic mutation is a significant risk factor for progression to a myeloid neoplasm. This study revealed the underlying molecular heterogeneity of isolated 20q- in the absence of morphologic features of a myeloid neoplasm, and underscored the prognostication value of genetic mutation analysis in these cases. Disclosures No relevant conflicts of interest to declare.